This is a preview of subscription content, log in via an institution to check access.
Reference
Scottish Medicines Consortium. SMC advice: crizotinib (Xalkori); lisdexamfetamine dimesylate (Elvanse); mirabegron (Betmiga); ranibizumab (Lucentis). Internet Document : 13 May 2013. Available from: URL: http://www.scottishmedicines.org.uk
Rights and permissions
About this article
Cite this article
SMC issues latest advice. PharmacoEcon Outcomes News 679, 10 (2013). https://doi.org/10.1007/s40274-013-0447-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0447-x